The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); BTG (Inst); Exelixis (Inst); Ipsen (Inst); Isotopen Technologien (Inst); Roche (Inst)
Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer
 
Masatoshi Kudo
Honoraria - Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Lilly Japan; MSD
Consulting or Advisory Role - BMS; Eisai; MSD; Ono Pharmaceutical; Roche
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Ono Pharmaceutical; Otsuka (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Heinz-Josef Klümpen
No Relationships to Disclose
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
Speakers' Bureau - Bayer
 
Philippe Merle
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Merck; Roche
Consulting or Advisory Role - Bayer Schering Pharma
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Gianluca Masi
No Relationships to Disclose
 
Catherine T. Frenette
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Merck
Speakers' Bureau - Abbvie; Bayer; Bristol meyers squibb; Eisai; Exelixis; Genentech; Gilead Sciences; Intercept Pharmaceuticals; Salix
Research Funding - Bayer (Inst); Exelixis (Inst); GENFIT (Inst); Merck (Inst)
 
Yoon Jun Kim
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb; Eisai
Consulting or Advisory Role - Bayer; Boston Scientific
Research Funding - AstraZeneca; BTG; Gilead Sciences
 
René Gerolami
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Masayuki Kurosaki
Consulting or Advisory Role - Bayer; Chugai Pharma; Eisai
Speakers' Bureau - Bayer; Chugai Pharma; Eisai; Lilly
 
Kazushi Numata
No Relationships to Disclose
 
Julia Pisarenko
Employment - ClinStat
 
Kirhan Ozgurdal
Employment - Bayer
 
Shukui Qin
No Relationships to Disclose